Welcome To Our Blog

The latest compounding news, articles and updates from our pharmacy network.

sterile compounding facility | newdrugloft.com

Sterile Ophthalmic Compounding: What Prescribers Should Know

The primary goal of healthcare providers is to ensure patient safety while providing the greatest health benefits to patients. Often, commercial medications fail to accomplish this goal for individuals due to a variety of reasons, including limited dosage forms, the presence of allergens, or other limiting options. In these and other situations, a patient-specific medication… Read more

two women sitting on a bench together | newdrugloft.com

Low-Dose Naltrexone (LDN) for Women’s Health

Although Women’s Health Month is over, we are continuing to focus on compounded preparations for women’s health in the second of our three-part blog series on women’s health. The first blog post about hormone replacement therapy can be found here. Naltrexone is an FDA-approved opioid antagonist used to manage alcohol use or opioid use disorder… Read more

white eye drop bottle | newdrugloft.com

Ophthalmic Compounding: Low-Dose Naltrexone (LDN) Eye Drops

Naltrexone is a competitive opioid receptor antagonist that provides a safe and relatively inexpensive method to treat various conditions. It is FDA-approved for treating alcohol dependence and preventing relapse to opioid dependence at doses of ≥ 50 mg, but it has also found a variety of off-label uses at much lower doses (generally ≤ 4.5… Read more

older woman smiling | newdrugloft.com

Hormone Replacement Therapy for Women’s Health Month

May is Women’s Health Month, so we’re focusing on hormone replacement therapy in the first of a three-part blog series on women’s health. In June and July, we’ll look at low-dose naltrexone (LDN) and vaginal/pelvic health.  On the heels of two major research developments on hormone replacement therapy (HRT) in women, now is the perfect… Read more


New Drug Loft and VLS Pharmacy Media Pieces

Explore New Drug Loft and VLS Pharmacy’s latest media features.

View Media